Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
NeoGenomics ( (NEO) ) has issued an announcement.
On June 19, 2025, NeoGenomics, Inc. expanded its Board of Directors from nine to ten members and appointed Marjorie C. Green as a new director. Dr. Green, who is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck, brings extensive experience in oncology and business development. Her appointment is expected to enhance NeoGenomics’ strategic direction in the precision oncology market, aligning with the company’s mission to improve patient care.
The most recent analyst rating on (NEO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.
Spark’s Take on NEO Stock
According to Spark, TipRanks’ AI Analyst, NEO is a Neutral.
The overall stock score reflects NeoGenomics’ growth potential tempered by profitability challenges. Positive earnings call sentiment and strategic leadership changes support the outlook, but technical and valuation metrics indicate caution.
To see Spark’s full report on NEO stock, click here.
More about NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. The company offers a comprehensive oncology-focused testing menu across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to aid in cancer diagnosis and treatment. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories in the US and a CAP-accredited laboratory in the UK.
Average Trading Volume: 2,282,516
Technical Sentiment Signal: Sell
Current Market Cap: $900.9M
See more insights into NEO stock on TipRanks’ Stock Analysis page.